拉坦前列素滴眼液与其复合剂的降眼压作用的比较

目的：评价0.005%拉坦前列素滴眼液＋0.5%噻吗洛尔滴眼液治疗原发性开角形青光眼患者的替代降眼压作用及其安全性。方法应用0.005%拉坦前列素滴眼液单一治疗的原发性开角型青光眼患者31例，给予0.005%拉坦前列素滴眼液＋0.5%噻吗洛尔滴眼液替代治疗。每晚点药1次，每次1滴。将连续点药后4、8、12周的眼压与基线眼压进行比较研究，同时观察血压、心率等全身及局部不良反应。结果0.005%拉坦前列素滴眼液＋0.5%噻吗洛尔滴眼液可以更有效降低眼压。连续点药4、8、12周后，与基线相比，眼压分别额外下降（2.2±1.1）mmHg、（2.0±0.9）mmHg、（2.2±1.0）mmHg，差异均具有统计学意义（P〈0.05）。连续点药4、8、12周后，获得至少2mmHg眼压下降值的患者百分率分别为64.5%、61.3%、64.5%。心动过缓（3.2%）是最严重的不良反应。结论0.005%拉坦前列素＋0.5%噻吗洛尔复方滴眼液能够更加有效的降低目标眼压，可以作为0.005%拉坦前列素滴眼液的替代治疗手段。

Efficacy of a switch to latanoprost + timolol maleate fixed combination eyedrops from latanoprost monotherapy

Objective To evaluate the intraocular pressure （IOP）-lowering effect and safety of latanoprost 0.005% ＋ timolol maleate 0.5% fixed combination eyedrops switching from latanoprost 0.005% monotherapy. Methods Thirty-one patients patients diagnosed with primary open-angle glaucoma who had an insufficient intraocular pressure （IOP） decrease with latanoprost 0.005%eyedrop monotherapy were enrolled. The latanoprost 0.005%eyedrops were discontinued,and administration of latanoprost 0.005%＋ timolol maleate 0.5% fixed combination eyedrops was initiated without any washout period. IOP was compared before and at weeks 4,8,and 12 after the switch. The incidence of adverse reactions was investigated at every follow-up visit. Results At 4,8, and 12 weeks after the switch,the mean reduction in IOP from baseline were 2.2±1.1mmHg,2.0±0.9mmHg,2.2±1.1mmHg respec-tively （P〈0.05）. At 4,8,and 12 weeks after the switch,the percentage of patients achieving ≥2mmHg reductions in IOP were 64. 5%,61.3%,64.5%. Bradycardia caused by fixed combination eyedrops was found in one （3.2%） patinet. Conclusion When la-tanoprost 0.005% eyedrop monotherapy was replaced by latanoprost 0.005% ＋ timolol maleate 0.5% fixed combination eyedrops , IOP decreased significantly.